RESP-X

News

UK biotech Infex is in hot pursuit of Insmed's Brinsupri, the only approved therapy for non-CF bronchiectasis, with its quarterly-dosed antibody.

News

The appetite among biotechs for IPOs shows no signs of being satisfied, with three more – ADARx, TRex, and Retension – making their intentions known.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.